Business
Namaste Announces Definitive Agreement to Commercialize Needle-Free Injector Technology for Medical Cannabis With Inolife R&D Inc. and Participates as Lead Order in Financing Round
Namaste Announces Definitive Agreement to Commercialize Needle-Free Injector Technology fo...
About this update from Lifeist Wellness Inc
[{"type":"text","content":"\n\n\n\nNamaste Announces Definitive Agreement to Commercialize Needle-Free Injector Technology for Medical Cannabis With Inolife R&D Inc. and Participates as Lead Order in Financing Round\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nNamaste Announces Definitive Agreement to Commercialize Needle-Free Injector Technology for Medical Cannabis With Inolife R&D Inc. and Participates as Lead Order in Financing Round\nCanada NewsWire\nVANCOUVER, May 23, 2018\n\n\n\nListed on the TSX Venture Exchange TSXV: N OTCQB: NXTTF Germany FSE: M5BQ\n\n\n\nVANCOUVER, May 23, 2018 /CNW/ - Namaste Technologies Inc. (\"Namaste\" or the \"Company\") (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that further to the Letter of Intent (\"LOI\") dated March 28th, 2018, the Company has signed a definitive agreement (the \"Agreement\") with Inolife R&D Inc. (\"Inolife\"), whereby Namaste is granted exclusive rights to the commercialization of Inolife's innovative needle-free technology for applications of medical cannabis, in accordance with Health Canada regulations. \n\n\n \n \n\n \nNamaste intends to produce medical cannabis oil through its partnership with Infinite Labz Inc. (\"Infinite Labz\") and to specifically formulate oil for use with Inolife's injector technology. The Company believes that needle-free injection of cannabis oils could prove to be one of the most effective means of dosing through a painless device, with a fast absorption rate. Namaste will work with Inolife's management team to develop standardized production procedures for oil production, and for testing or studies required to commercialize the technology for applications of medical cannabis in accordance with federal regulations.\n\nNamaste is also pleased to announce that the Company is participating as the lead order in a non-brokered private placement offering (\"Private Placement\"), whereby Namaste will purchase 2,000,000 units of Inolife, issued at a price of $0.10 per unit. Each unit consists of one common share and one-half of one common share purchase ...